Specialty Pharmacy

Bavencio (avelumab) is indicated to treat metastatic Merkel cell carcinoma.

New research indicates that high consumption of certain dairy products may either increase or decrease the risk of developing breast cancer, depending on the food.

Monthly and annual spending limits would likely benefit Part D enrollees.

Genentech’s $100,000 grant will fund a home-based telemedicine program.

Policies targeting both physicians and hospitals could reduce wasteful health care spending.

Mapping lung cancer cell interactions can unveil new targeted treatment techniques.

Jonathan Van Lare, PharmD, director of Clincal Services at Pharmacy Advantage, discusses the elements of a successful specialty pharmacy therapy management program.

Vitamin C observed to kill cancer stem-like cells.

Leading cardiologists say it is difficult to get their patients access to evolocumab.

Marker helps differentiate dormant HIV-infected cells from their health counterpart cells.

Top news of the day from across the health care landscape.

Nanomachines produce a florescent response when in contact with cancer biomarkers.

Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.

Muscle composition may be predictive of chemotherapy toxicity.

Clinical practice guideline on human papillomavirus (HPV) vaccination can improve prevention of cervical cancer.

Cancer-focused continuing education programs seek to enhance cancer care at specialty pharmacies.

Epic EHR system will be used among CVS Specialty Pharmacies.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses whether increased competition for specialty drugs can lower costs.

Antibody therapy enables efficacious control of HIV-like virus in monkeys.

Need for an increase in HCV testing awareness among health care providers and baby boomers.

Researchers will investigate factors that may contribute to poor cancer outcomes among African Americans.

Study links anti-tumor immunity to islet autoimmunity.

Top news of the day from across the health care landscape.

The risk of a second cancer remained high even 30 years after treatment.

Progression-free survival with IMMU-132 increases from an average of 3.5 months to 16.6 months in patients with breast cancer.

Round 2 of study finds a reduction in start time of antiretroviral therapy for HIV treatment.

TP53 alteration seen among 49% of patients receiving first-line treatment for renal cell carcinoma.

Test delivers the results of a multiple sclerosis diagnosis in as few as 7 days.